Overview
Provider Statement
This continuing medical education activity is provided by 
.
Support Statement
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
Activity Description
Early diagnosis and prompt treatment of diabetic retinopathy (DR) has been shown to effectively prevent vision loss. Until recently, panretinal photocoagulation was the primary management approach for DR. However, clinical trial data from pinnacle studies utilizing anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema have demonstrated that anti-VEGF therapy is also an effective treatment option for patients with DR. Specific data on the optimal use of anti-VEGF agents to treat DR have emerged from both initial studies establishing the effectiveness of anti-VEGF in this setting and subsequent clinical trials. Within this recorded educational symposium, experts in the field evaluate new findings pertaining to the optimization of treatment dosing and management of patients with DR, compare treatment protocols for proliferative versus nonproliferative DR, and assess treatment regimens for their ability to achieve regression of DR.
Target Audience
The intended audience for the activity is retina specialists and other health care professionals involved in the management of patients with DR.
Learning Objective(s)
Upon successful completion of this activity, participants should be better able to:
- Evaluate new findings pertaining to the optimization of treatment dosing and management of patients with DR.
- Compare treatment protocols for proliferative versus non-proliferative DR.
- Assess treatment regimens for their ability to achieve regression of DR.
Activity Chair
Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH
Faculty
W. Lloyd Clark, MD
Palmetto Retina Center, LLC
Assistant Clinical Professor of Ophthalmology
University of South Carolina
School of Medicine
Columbia, SC
Dilsher S. Dhoot, MD
Vitreoretinal Surgeon
California Retina Consultants
Santa Barbara, CA
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 19, 2019, through December 18, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationship(s)
W. Lloyd Clark, MD
Consulting Fee: Genentech/Roche, Regeneron
Speakers Bureau: Genentech/Roche, Regeneron
Contracted Research: Genentech/Roche, Regeneron
Dilsher S. Dhoot, MD
Consulting Fees: Alimera, Allegro, Allergan, EyePoint, Genentech, Novartis, Ocular Therapeutix, Regeneron, Santen
Speakers Bureau: Alimera, Genentech, Novartis, Regeneron
Rishi P. Singh, MD
Consulting Fees: Alcon/Novartis, Genentech, Optos, Regeneron, Zeiss
Contracted Research: Apellis
Reviewer reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at [email protected]
Recent Comments